This case study involved a 30-year-old G3P2 patient. In the previous two pregnancies, she experienced toxemia of pregnancy with intrauterine growth retardation. Autoantibodies were found to be positive in these two pregnancies. In her third pregnancy, Shakuyakukanzou-tou with low doses of aspirin were administered. Her autoantibody continued to be negative. Toxemia was not noted and fetus growth was adequate for her date. This data suggests that Shakuyaku-kanzou-tou may be effective for autoimmune pregnant disorders involving intrauterine growth retardation.

Sixty-five patients who complained of various unidentified symptoms (undefined clinical syndrome), including 59 with climacteric syndrome, received Kampo medicine for eight weeks or more according to scores for their body constitution. Saiko-keishi-kankyo-to was given to those with a deficient constitution, Saiko-karyukotsu-borei-to to those with a robust constitution, and Kami-shoyo-san to those with a medium constitution.
A deficient constitution was more common among those aged 40 to 49, while those with a robust constitution increased in patients aged 50 to 59. The pretreatment climacteric index was comparable among the three groups, and most of them were mild to moderate. The faces of those with a robust constitution had more gloss and a tenser texture while those with deficient constitution were paler and had a face with less of a tense texture. Other signs such as a repeated epigastric splashing sound, hypochondriac resistance, dark rings around the eyes, dark purple tongue, and paraumbilical resistance were similar between those with robust and deficient constitutions. These signs were mild and observed in about 90% of patients. They therefore appear to be common signs among patients suffering from undefined clinical syndrome.
The severity of conditions determined by the mean value of the climacteric index was moderate among those with robust to medium constitutions and mild among those with deficient constitutions. The index was reduced to the normal values within two weeks of starting Kampo medicine in those with a deficient constitution, within six weeks in those with a medium constitution, and within eight weeks in those with a robust constitution. The mean values of clinical laboratory test results and hormone levels remained unchanged during treatment (eight weeks).
The overall improvement rating (“markedly improved” plus “improved”) was high (80%) in those with a deficient constitution, and slightly above 60% in those with a medium and a robust constitution. Safety was very high in all Kampo medicine used. The clinical value (“very useful” plus “useful”) was highest with Saiko-keishi-kankyoto given to those with a deficient constitution, followed by Kami-shoyo-san given to those with a medium constitution and Saiko-ka-ryukotsu-borei-to given to those with a robust constitution in that order.

We investigated the clinical effect of Juzen-taiho-to and macrophage-colony stimulating factor (M-CSF) on thrombocytopenia induced by anti-cancer chemotherapy in gynecologic malignancies. We discussed 31 courses in 20 patients. Juzen-taiho-to and/or M-CSF were given when indicated from serum platelet level. Twenty-eight courses (90.3%) in 17 patients did not need transfusion of platelet, and 3 courses in 3 patients needed it. It suggested that Juzen-taiho-to and M-CSF might be effective. As platelet-free plasma TGF-β1 level during the treatment of Juzen-taiho-to alone was remarkably increased, it might enhance the antitumoral action. Accordingly, combination treatments of Juzen-taiho-to and M-CSF might be effective for thrombocytopenia induced by anti-cancer chemotherapy.